Precision oncology company developing integrated therapeutic (Rx) and diagnostic (Dx) approaches
Ignyta (NASDAQ: RXDX) is advancing the concept of "precision oncology" through development of targeted therapeutics in parallel with companion diagnostics to identify patients most likely to respond to a drug. The company has a broad pipeline, including lead product RXDX-101 which inhibits multiple kinases (including TrkA, TrkB, TrkC, ROS1, and Alk) which are frequently altered in a range of solid tumors. Ignyta completed its IPO on NASDAQ in 2014 and was acquired by Roche in 2018.
